نتائج البحث - Ruth Aranda

  • يعرض 1 - 6 نتائج من 6
تنقيح النتائج
  1. 1
    The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

    The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy حسب David M. Briere, Niranjan Sudhakar, David M. Woods, Jill Hallin, Lars D. Engstrom, Ruth Aranda, Harrah Chiang, Andressa L. Sodré, Peter Olson, Jeffrey S. Weber, James G. Christensen

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

    The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy حسب David M. Briere, Shuai Li, Andrew Calinisan, Niranjan Sudhakar, Ruth Aranda, Lauren Hargis, David H. Peng, Jiehui Deng, Lars D. Engstrom, Jill Hallin, Sole Gatto, Julio Fernandez-Banet, Adam Pavlı́ček, Kwok‐Kin Wong, James G. Christensen, Peter Olson

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted Cancers

    Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted Cancers حسب Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski, David M. Briere, Aaron C. Burns, James G. Christensen, Jeffery Clarine, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, Ronald Jean-Baptiste, John M. Ketcham, Masakazu Kobayashi, Jon Kuehler, Svitlana Kulyk, J. David Lawson, Krystal Moya, Peter Olson, Lisa Rahbæk, Nicole C. Thomas, Xiaolun Wang, Laura Waters, Matthew A. Marx

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models

    Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors... حسب Lars D. Engstrom, Ruth Aranda, Matthew Lee, Elizabeth A. Tovar, Curt J. Essenburg, Zachary Madaj, Harrah Chiang, David M. Briere, Jill Hallin, Pedro P. López‐Casas, Natalia Baños, Camino Menéndez, Manuel Hidalgo, Vanessa Tassell, Richard C. Chao, Darya Chudova, Richard B. Lanman, Peter Olson, Lyudmila Bazhenova, Sandip Pravin Patel, Carrie R. Graveel, Mizuki Nishino, Geoffrey I. Shapiro, Nir Peled, Mark M. Awad, Pasi A. Jänne, James G. Christensen

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i>-Deleted Cancer

    MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i>-Deleted Cancer حسب Lars D. Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R. Smith, Svitlana Kulyk, J. David Lawson, Leo He, Laura D. Hover, Julio Fernandez-Banet, Jill Hallin, Darin Vanderpool, David M. Briere, Alice Blaj, Matthew A. Marx, Jordi Rodón, Michael Offin, Kathryn C. Arbour, Melissa L. Johnson, David J. Kwiatkowski, Pasi A. Jänne, Candace L. Haddox, Kyriakos P. Papadopoulos, Jason T. Henry, Konstantinos Leventakos, James G. Christensen, Ronald Shazer, Peter Olson

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

    The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients حسب Jill Hallin, Lars D. Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M. Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R. Baer, Joshua A. Ballard, Michael Burkard, Jay B. Fell, John P. Fischer, Guy Vigers, Jenny Y. Xue, Sole Gatto, Julio Fernandez-Banet, Adam Pavlı́ček, Karen Velastagui, Richard C. Chao, Jeremy Barton, Mariaelena Pierobon, Elisa Baldelli, Emanuel F. Patricoin, Douglas P. Cassidy, Matthew A. Marx, Igor I. Rybkin, Melissa L. Johnson, Sai‐Hong Ignatius Ou, Piro Lito, Kyriakos P. Papadopoulos, Pasi A. Jänne, Peter Olson, James G. Christensen

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: